Correlation Between Crinetics Pharmaceuticals and Humacyte
Can any of the company-specific risk be diversified away by investing in both Crinetics Pharmaceuticals and Humacyte at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Crinetics Pharmaceuticals and Humacyte into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Crinetics Pharmaceuticals and Humacyte, you can compare the effects of market volatilities on Crinetics Pharmaceuticals and Humacyte and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Crinetics Pharmaceuticals with a short position of Humacyte. Check out your portfolio center. Please also check ongoing floating volatility patterns of Crinetics Pharmaceuticals and Humacyte.
Diversification Opportunities for Crinetics Pharmaceuticals and Humacyte
-0.22 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Crinetics and Humacyte is -0.22. Overlapping area represents the amount of risk that can be diversified away by holding Crinetics Pharmaceuticals and Humacyte in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Humacyte and Crinetics Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Crinetics Pharmaceuticals are associated (or correlated) with Humacyte. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Humacyte has no effect on the direction of Crinetics Pharmaceuticals i.e., Crinetics Pharmaceuticals and Humacyte go up and down completely randomly.
Pair Corralation between Crinetics Pharmaceuticals and Humacyte
Given the investment horizon of 90 days Crinetics Pharmaceuticals is expected to generate 1.37 times less return on investment than Humacyte. But when comparing it to its historical volatility, Crinetics Pharmaceuticals is 2.12 times less risky than Humacyte. It trades about 0.08 of its potential returns per unit of risk. Humacyte is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest 341.00 in Humacyte on August 29, 2024 and sell it today you would earn a total of 102.00 from holding Humacyte or generate 29.91% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Crinetics Pharmaceuticals vs. Humacyte
Performance |
| Timeline |
| Crinetics Pharmaceuticals |
| Humacyte |
Crinetics Pharmaceuticals and Humacyte Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Crinetics Pharmaceuticals and Humacyte
The main advantage of trading using opposite Crinetics Pharmaceuticals and Humacyte positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Crinetics Pharmaceuticals position performs unexpectedly, Humacyte can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Humacyte will offset losses from the drop in Humacyte's long position.| Crinetics Pharmaceuticals vs. Viridian Therapeutics | Crinetics Pharmaceuticals vs. Cytokinetics | Crinetics Pharmaceuticals vs. Structure Therapeutics American | Crinetics Pharmaceuticals vs. Passage Bio |
| Humacyte vs. Crinetics Pharmaceuticals | Humacyte vs. Viridian Therapeutics | Humacyte vs. Cytokinetics | Humacyte vs. Structure Therapeutics American |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Complementary Tools
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |